Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding
Executive Summary
New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.
You may also be interested in...
Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements
Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.
What's Driving Price Increases For Addiction Treatment Drugs?
At House hearing, PhRMA representative cites introduction of innovative delivery systems while GPhA exec points to manufacturing costs; state attorneys general file Suboxone 'product hopping' suit.
Actavis Completes Sales Reorganization, Pipeline Rationalization
The company will move forward with 70 pipeline candidates following the closing of the Allergan merger, Senior VP-Brand R&D David Nicholson said during the company’s first quarter earnings call.